Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Brooke Pereira

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3513-1214; OpenAlex author ID A5085027792. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 15

  1. Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer. Co-author DOI 10.1038/s41467-026-69398-w↗
  2. A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer Co-author DOI 10.64898/2026.05.20.726559↗
  3. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  4. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  5. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  6. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  7. Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy. Co-author DOI 10.1042/bst20220162↗
  8. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  9. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  10. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  11. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  12. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Last author DOI 10.3390/cancers13143481↗
  13. Targeting genetically-tuned CAFs in pancreatic cancer via perlecan manipulation. First author DOI 10.1080/14728222.2020.1727887↗
  14. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. Co-author DOI 10.1016/j.trecan.2019.09.010↗
  15. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul Timpson · 8 shared papers, 2019–2026 · strength 1.25
  2. David Herrmann · 5 shared papers, 2019–2026 · strength 0.77
  3. Kendelle Joan Murphy · 3 shared papers, 2021–2022 · strength 0.44
  4. Cecilia R. Chambers · 3 shared papers, 2019–2021 · strength 0.35
  5. Claire Vennin · 3 shared papers, 2019–2021 · strength 0.34
  6. Thomas R. Cox · 3 shared papers, 2019–2021 · strength 0.26
  7. Jennifer P. Morton · 3 shared papers, 2019–2021 · strength 0.26
  8. Shona Ritchie · 2 shared papers, 2020–2021 · strength 0.24
  9. Nina G. Steele · 1 shared paper, 2026 · strength 0.24
  10. Kathryn E. Maraszek · 1 shared paper, 2026 · strength 0.24
  11. Michael E. Feigin · 1 shared paper, 2026 · strength 0.24
  12. Hunter D. Reavis · 1 shared paper, 2026 · strength 0.24
  13. Janusz Franco‐Barraza · 1 shared paper, 2026 · strength 0.24
  14. Edna Cukierman · 1 shared paper, 2026 · strength 0.24
  15. Yu Chinn Joshua Chey · 1 shared paper, 2026 · strength 0.23
  16. Joanne Lundy · 1 shared paper, 2026 · strength 0.23
  17. Daniel Gerald Croagh · 1 shared paper, 2026 · strength 0.23
  18. Brendan John Jenkins · 1 shared paper, 2026 · strength 0.23
  19. Angela S. Y. Chou · 2 shared papers, 2021 · strength 0.16
  20. Amber L. Johns · 2 shared papers, 2021 · strength 0.16
  21. Marina Pajic · 2 shared papers, 2021 · strength 0.16
  22. Anthony James Gill · 2 shared papers, 2021 · strength 0.16
  23. Owen James Sansom · 2 shared papers, 2021 · strength 0.16
  24. David Goldstein · 1 shared paper, 2021 · strength 0.08
  25. Val Gebski · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.